Scholarlink

Background <p>The efficacy of glucocorticoid (GC) in the management of immunoglobulin A nephropathy (IgAN) remains highly controversial. The study was conducted to analyze the efficacy and kidney outcomes of GC in the treatment of pediatric IgAN.</p> Methods <p>Using the follow-up data of children with chronic kidney disease from the Department of Pediatrics at Jinling Hospital between January 2000 and December 2020, we selected children with primary IgAN who were ≤ 18&#xa0;years old, confirmed by kidney biopsy, and had undergone regular follow-up for more than 2&#xa0;years. Patients who had previously used other immunosuppressive agents or had not received renin-angiotensin system blocker (RASB) treatment were excluded. The selected patients were divided into two groups based on their prior treatment regimens: the GC + RASB group and the RASB group. The primary outcome was a composite of a 40% decrease in estimated glomerular filtration rate (eGFR) from baseline, kidney failure, or death due to kidney disease.</p> Results <p>A total of 374 patients (149 females) were enrolled, with 230 in the GC + RASB group and 144 in the RASB group. At baseline, the GC + RASB group had lower albumin and higher creatinine levels (all <i>P</i> &lt; 0.05). From 6&#xa0;months of treatment, the GC + RASB group showed higher urinary protein remission rates (<i>P</i> &lt; 0.05), but hematuria relief was similar between groups. Adverse events, including centripetal obesity, were more frequent in the GC + RASB group (<i>P</i> = 0.001). After a median follow-up of 130.97&#xa0;months, the GC + RASB group had fewer endpoint events (5.22% vs. 11.11%, <i>P</i> = 0.035) and higher cumulative kidney event-free survival rates, particularly in patients with eGFR &gt; 50&#xa0;ml/min/1.73&#xa0;m<sup>2</sup> and 24&#xa0;h-UP ≥ 1&#xa0;g/d (all <i>P</i> &lt; 0.05).</p> Conclusions <p>GC therapy reduced the risk of progression to kidney failure in children with initial eGFR &gt; 50&#xa0;ml/min/1.73 m<sup>2</sup> and proteinuria ≥ 1&#xa0;g/d. No additional kidney event-free survival benefit was observed in children with eGFR ≤ 50&#xa0;ml/min/1.73 m<sup>2</sup> or proteinuria &lt; 1&#xa0;g/d.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Retrospective analysis of glucocorticoid therapy in pediatric immunoglobulin A nephropathy: Kidney outcomes and efficacy

  • 期刊论文

  • 发表日期：

    2025年7月15日

查看全文
  • Heyan Wu,
  • Zhengkun Xia,
  • Lidan Zhang

摘要

Background

The efficacy of glucocorticoid (GC) in the management of immunoglobulin A nephropathy (IgAN) remains highly controversial. The study was conducted to analyze the efficacy and kidney outcomes of GC in the treatment of pediatric IgAN.

Methods

Using the follow-up data of children with chronic kidney disease from the Department of Pediatrics at Jinling Hospital between January 2000 and December 2020, we selected children with primary IgAN who were ≤ 18 years old, confirmed by kidney biopsy, and had undergone regular follow-up for more than 2 years. Patients who had previously used other immunosuppressive agents or had not received renin-angiotensin system blocker (RASB) treatment were excluded. The selected patients were divided into two groups based on their prior treatment regimens: the GC + RASB group and the RASB group. The primary outcome was a composite of a 40% decrease in estimated glomerular filtration rate (eGFR) from baseline, kidney failure, or death due to kidney disease.

Results

A total of 374 patients (149 females) were enrolled, with 230 in the GC + RASB group and 144 in the RASB group. At baseline, the GC + RASB group had lower albumin and higher creatinine levels (all P < 0.05). From 6 months of treatment, the GC + RASB group showed higher urinary protein remission rates (P < 0.05), but hematuria relief was similar between groups. Adverse events, including centripetal obesity, were more frequent in the GC + RASB group (P = 0.001). After a median follow-up of 130.97 months, the GC + RASB group had fewer endpoint events (5.22% vs. 11.11%, P = 0.035) and higher cumulative kidney event-free survival rates, particularly in patients with eGFR > 50 ml/min/1.73 m2 and 24 h-UP ≥ 1 g/d (all P < 0.05).

Conclusions

GC therapy reduced the risk of progression to kidney failure in children with initial eGFR > 50 ml/min/1.73 m2 and proteinuria ≥ 1 g/d. No additional kidney event-free survival benefit was observed in children with eGFR ≤ 50 ml/min/1.73 m2 or proteinuria < 1 g/d.

Graphical abstract